1.Golden section, the optimization of environmental factors for human body
Chinese Journal of Tissue Engineering Research 2006;10(45):227-228
OBJECTIVE: Human body is closed in environmental physical factors.Using golden section, this study aims to find out the best condition of environmental physical factors acting on human body.METHODS: There are a lot of phenomena which have relation with golden section, for example, the environmental temperature, humidity, light frequency, sound intensity, atmospheric pressure, oxygen content, etc. Are in step with human sensation. RESULTS: ① Harmony between environmental temperature and human body: Room temperature was maintained at 22-24 ℃, which was the golden temperature of human body (37 ℃). At this time, human felt the most comfortable. ② Harmony between humidity and human body: When humidity ranged from 60% to 69% which contained the golden humidity of 61.8%, human did not feel both dryness and wetness. ③ Harmony between light frequency and human body: Visible light with the wave length of 5.3×10-5 cm exactly stood at the golden point and was located in the area between yellow and green, I.e. Kelly light. Eyes of human had various sensitivities to each part of visible light. The further the wave-length away from kelly light, the poorer the sensitivity was; therefore, photosensitivity of kelly light was the most obvious, and human felt comfortable at the same time. ④ Harmony between sound intensity and human body: Golden value from auditory threshold (0 dB) to pain threshold (120 dB) was 45.84 dB and 74.16 dB, respectively, which was located at normal area (40-60 dB),loudness area (60-80 dB) and region of musical sound. Musical sound had a great effect on cardiovascular system, digestive system, gland excretionand thinking activities. ⑤ Harmony between atmospheric pressure and human body: If oxygen content was near to golden value, human felt suitable;otherwise, human would have hypoxia, irritancy, nausea and emesis.CONCLUSION: The best condition of environmental physical factors is optional. If the indexes, such as environmental temperature, humidity, light frequency, sound intensity, atmospheric pressure and oxygen content, are near to golden value, they will be harmonious with human body.
2.Differences of critical twinkle visual frequency for red light among normal persons,schizophrenia and alcoholism patients
Chinese Journal of Tissue Engineering Research 2007;0(22):-
0.05).CONCLUSION:The critical twinkle visual frequency of red light in normal persons is higher than that in schizophrenia patients and alcoholism patients.And the critical twinkle visual frequency in alcoholism patients is a little lower than that in schizophrenia patients.
3.Research progress of rat models of type 2 diabetes induced by high calorie diet combined with streptozotocin
Acta Laboratorium Animalis Scientia Sinica 2014;(4):90-93
The establishment of rat models of type 2 diabetes mellitus can provide an ideal animal experimental technology platform for the research of pathogenesis , prevention , diagnosis and treatment of diabetes mellitus and its com-plications .The establishment of type 2 diabetic rat models may be affected by various factors .In this paper , the main fac-tors, streptozotocin (STZ) application, high fat and calorie diet, selection and breeding of rats are reviewed , which will provide an important reference for the development of rat models type 2 diabetes.
4. The application of UGT1A1 28 genotype combined with pharmacokinetics of SN-38 in the detection of irinotecan-based second-line chemotherapy in patients with advanced colorectal cancer
Tumor 2013;33(2):181-189
Objective: This multicenter study was conducted to retrospectively investigate the gene polymorphism of UGT 1A 1 28 (uridine diphosphate glucuronosyl transferase 1A1 28) in patients with advanced colorectal cancer receiving CPT-11 (irinotecan)-based second-line chemotherapy between June 2010 and January 2012. The associations between peak and valley concentrations of SN-38 with the efficacy and adverse effects of these patients carrying genotype (TA)6/(TA)6 or (TA)6/(TA)7 after chemotherapy with CPT-11. Methods: This was a retrospective multicenter study. Sixty-nine patients with advanced colorectal cancer receiving CPT-11 (irinotecan)-based second-line chemotherapy between June 2010 and January 2012 were collected. The frequency of TA repeats in the TATA box region of the UGT 1A 1 gene was detected before chemotherapy and the plasma concentration of SN-38 was detected by HPLC (high-performance liquid chromatography) at 1.5 h and 49.0 h after CPT-11 infusion. The shortterm response and adverse effects were observed. The relationships of the concentration of plasma SN-38 with the short-term response and adverse effects of patients carrying genotype (TA) 6/(TA)6 or (TA)6/(TA)7 were analyzed by stepwise regression analysis. Results: Of sixty-nine patients, (TA) 6/(TA)6 genotype was identified in forty-five patients (65.22%), (TA)6/(TA)7 genotype was identified in twenty-four patients (34.78%), and (TA)7/(TA)7 genotype was identified in none patients. The average plasma peak and valley concentrations of SN-38 after CPT-11 infusion in patients carrying (TA) 6/(TA)7 genotype were both significantly higher than those in patients carrying (TA)6/(TA)6 genotype (P = 0.001, P = 0.000). Stepwise regression analysis showed that for patients carrying (TA)6/(TA)6 genotype, the peak plasma concentration of SN-38 was related with progression-free survival, and the valley plasma concentration of SN-38 was related with short-term response; for patients carrying (TA)6/(TA)7 genotype, the peak plasma concentration of SN-38 was related with bone marrow suppression, and the valley plasma concentration of SN-38 was related with plasma total bilirubin level and delayed diarrhea after CPT-11 infusion. For patients carrying (TA) 6/(TA)6 genotype, the median progression-free survival of patients whose peak plasma concentration of SN-38 was above 43.20 ng/mL and the valley plasma concentration of SN-38 was above 9.41 ng/mL was significantly prolonged as compared with that of the patients whose peak plasma concentration of SN-38 was less than or equal to 43.20 ng/mL (6.0 vs 4.6 months, χ2 = 25.57, P = 0.00) and the valley plasma concentration of SN-38 was less than or equal to 9.41 ng/mL (6.0 vs 5.2 months, χ2 = 6.81, P = 0.01). For patients carrying (TA)6/(TA)7 genotype, the median progression-free survival of patients whose peak plasma concentration of SN-38 was above 50.60 ng/mL and the valley plasma concentration of SN-38 was above 16.29 ng/mL was not significantly prolonged as compared with that of the patients whose peak plasma concentration of SN-38 was less than or equal to 50.60 ng/ mL (7.0 vs 6.0 months, χ2 = 0.18, P = 0.67) and the valley plasma concentration of SN-38 was less than or equal to 16.29 ng/mL (6.0 vs 7.3 months, χ2 = 0.56, P = 0.46); the rates of bone marrow suppression (P = 0.02, P = 0.02) and delayed diarrhea were higher (P = 0.04, P = 0.03). Conclusion: The genotypes of (TA)6/(TA)6 and (TA)6/(TA)7 account for the majority of advanced colorectal cancer. For patients carrying (TA)6/(TA)6 genotype, CPT-11 dosage can be increased gradually to improve the response of patients with peak plasma concentration of SN-38 ≤ 43.20 ng/mL or peak valley concentration of SN-38 ≤ 9.41 ng/mL after CPT-11 infusion; for patients carrying (TA)6/(TA)7 genotype, CPT-11 dosage can be reduced appropriately to reduce serious adverse effects without affecting the response of patients with peak plasma concentration of SN-38 > 50.60 ng/mL or peak valley concentration of SN-38 > 16.29 ng/mL after CPT-11 infusion. Copyright © 2013 by TUMOR.
5. The role of pharmacokinetic monitoring of fluorouracil in improvement of efficacy and reduction of adverse reactions for patients with advanced gastric cancer
Tumor 2011;31(10):930-936
Objective: To retrospectively investigate the relationship between plasma concentration of fluorouracil and its therapeutic efficacy as well as adverse reactions in 70 patients with locally advanced or metastatic gastric cancer, and to determine the role of pharmacokinetic monitoring of fluorouracil in improvement of efficacy and reduction of adverse reactions of fluorouracil-based chemotherapy. Methods: Seventy patients with unresectable locally advanced or metastatic gastric cancer were randomly assigned into group A [treated with DCF regimen (docetaxol+cisplatin+fluorouracil), repeated every three weeksfor at least four cycles] and group B [treated with DOF regimen (docetaxol+oxaliplatin+fluorouracil), repeated every three weeks for at least four cycles]. The plasma concentration of fluorouracil was detected by high performance liquid chromatography (HPLC) (time for detection: 4-6 AM) after continuous infusion of fluorouracil over 12 h in each cycle. The average value of plasma concentrations in each cycle was calculated, and the factors related to plasma concentration of fluorouracil were screened by stepwise regression. Then all patients were divided into three groups (group 1, group 2 and group 3) according to the predictive confidence interval of plasma fluorouracil concentration, and the average values of plasma fluorouracil concentration in each cycle of these three groups were less than or equal to 25.5 mg/L25.6-37.4 mg/L, and more than 37.4 mg/L, respectively. The relationship between plasma concentration of fluorouracil and its therapeutic efficacy as well as adverse reactions was retrospectively analyzed. Results: Stepwise regression analysis showed that the plasma concentration of fluorouracil was associated with myelosuppression, mucositis, progression-free survival (PFS) and overall survival (OS). The average plasma concentrations of fluorouracil in group 1, group 2 and group 3 were (20.73±3.80) mg/L, (31.98±3.10) mg/L and (40.32±3.45) mg/L, respectively (χ2=66.24, P <0.001). As for efficacy, the medianPFS and OS of group 2 and group 3 were both significantly higher than those of group 1 [PFS: (6.00±0.32), (7.50±0.75) and (4.50±0.19) months, χ2=2.09, P <0.001; O S: (13.00±1.58), (12.50±2.66) and (8.50±1.00) months, χ2=32.32, P <0.001]. In terms of adverse reactions, the incidence rates of bone marrow suppression and mucositis of group 3 were both higher than those of group 1 and group 2 (P =0.04 and P =0.03). Conclusion: The patients with advanced gastric cancer receiving fluorouracil-based chemotherapy with an average plasma concentration of fluorouracil maintained within the range of 25.6-37.4 mg/L can obtain better survival and tolerance as well as lower incidence rates of adverse reactions such as myelosuppression (especially III/IV), mucositis, etc. Copyright© 2011 by TUMOR.
6.Targeting angiogenesis and vascular remodeling as a novel therapeutic approach to liver fibrosis.
Xun-xun WU ; Cai-zhen ZHANG ; Xin WANG ; Yong DIAO
Acta Pharmaceutica Sinica 2015;50(5):535-540
Development of liver fibrosis is closely associated with angiogenesis and abnormal vascular remodeling. Recent studies have highlighted the importance of angiogenesis and vascular remodeling in fibrogenesis, the results that inhibition of angiogenesis is effective in suppression of liver fibrosis demonstrate that therapies with several molecular targets against angiogenesis, inflammation and fibrosis might be beneficial for the treatment of cirrhosis. However, there is some evidence that inhibition of angiogenesis can even worsen fibrosis. This article outlines recent advances regarding the interplay between inflammation, angiogenesis and fibrogenesis in terms of cellular and molecular mechanisms, and suggests a requirement of greater understanding to intervene in these key processes, such as liver sinusoidal endothelial cell fenestration and impact distinct chemokine actions driving monocyte migration and differentiation, for therapeutic benefit in the future.
Humans
;
Inflammation
;
therapy
;
Liver Cirrhosis
;
therapy
;
Neovascularization, Pathologic
;
therapy
;
Vascular Remodeling
7.The protection of Atomolan on Ischemia-reperfnsion injury of the rat bile duct cells in liver transplantation
Li LU ; Junwei SHAO ; Xun CAI
Journal of Chinese Physician 2008;10(9):1188-1190
Objective To explore the mechanisms of ischemia-reperfasion(I/R)injury of the bile duet and the effect of Atomolan on Isehemia-reperfusion injury of the bile duct in liver transplantation.Methods Pathological changes of the bile duct cells in three groups of rat liver transplantation model were observed through light microscope.And the effective protection of Atomolan against ischemia-repeffusion injury was observed.Results In ischemia-reperfusion group,the injury of bile duct cells were more serious,the level of ALT,AST and γ-glutamyhransferase elevated higher,oxygen free radical generated more,and the apoptosis of bile duct ceils appeared more,compared with Atomolan pretreatment.Conclusion The injury in bile duct cells is more serious than that in hepatoeyte in I/R injury.Atomolan can provide effective protection against liver Ischemia-reperfusion injury.The mechanisms may be through depress the production of oxygen free radical and decrease the apoptosis of bile duct cells.
8.MiRNA-106a Induces Multidrug Resistance of Gastric Cancer Cells by Targeting RUNX 3
Yi ZHANG ; Xun CAI ; Weidong JIN
Acta Medicinae Universitatis Scientiae et Technologiae Huazhong 2015;(1):42-46,73
Objective To explore the effect of miRNA‐106a(miR‐106a) expression on multidrug resistance(MDR)of gastric cancer(GC)cells and the involvement of runt‐related transcription factor 3 RUNX3.Methods The expression of miR‐106a was detected in two human gastric adenocarcinoma cell lines with MDR by immunoblotting and apoptosis assay. The sensitivity of GC cells to anticancer drugs was observed by detecting the expression of miR‐106a by using immunoblotting and PCR ,and the relationship between miR‐106a and RUNX3 was determined by luciferase activity assay.Results miR‐106a was significantly in‐creased in GC cells with MDR ,and it suppressed the sensitivity of GC cells to anticancer drugs. It could modulate MDR by tar‐geting RUNX3.Conclusion miR‐106a can induce the MDR by targeting RUNX3 in GC.
9.Effectiveness of early goal-directed fluid therapy with fresh frozen plasma for severe acute pancre-atitis
Yang ZHANG ; Xun CAI ; Jiaxin YE
Journal of Clinical Surgery 2015;(1):30-32,35
Objective To evaluate the effect of early goal-directed fluid therapy with fresh frozen plasma in severe acute pancreatitis(SAP). Methods From January 2010 to June 2014,79 SAP patients were enrolled according to the continuous sampling method. All the patients were randomly divided into a control group who accept the traditional fluid therapy(group A),an experimental group 1 who accept early goal-directed fluid therapy(group B),and an experimental group 2 who accept the early goal-directed fluid therapy with fresh frozen plasma(group C). There were no significant differences of general conditions a-mong groups. The differences of ICU admission,mortality and occurrence rate of abdominal compartment syndrome(ACS)and MODS were compared among groups. Results Compared with group A,group B and C have a shorter length of ICU admission,a lower mortality and a lower occurrence rate of ACS and MODS (P < 0. 05). Compared with group B,group C have a shorter length of ICU admission,a lower mortality and a lower occurrence rate of ACS and MODS(P < 0. 05). Conclusion The method of early goal-direct-ed fluid therapy with fresh frozen plasma will contribute to shorten the length of ICU admission and reduce mortality and occurrence rate of ACS and MODS for patients with SAP.
10.A clinical study of the prognostic value of modified Glasgow prognostic score in patients with gas- tric cancer
Journal of Clinical Surgery 2014;(10):746-748
Objective To investigate the prognostic value of modified Glasgow prognostic score(mGPS)in patients with gastric cancer.Methods The clinical data of 600 patients with gastric cancerwho underwent surgical treatment were retrospectively reviewed.These patients were divided into themGPS0 group,mGPS1 group,and mGPS2 group according to the standard of mGPS.Postoperative survivals and risk factors that may affect patient's prognosis were analyzed among the three groups.Results There were 46 (7.7%)cases,33 (5.5%)cases and 521 (86.8%)cases in the mGPS0,mGPS1 andmGPS2 group,respectively.Except for gender(P =0.203),age,BMI,CEA,CA199,CRP,Alb,TNM stageand mGPS affected the over all survivals and there were significant differences among the groups(P <0.01).Gender,age,BMI,CEA,CA199 and TNM stage affected the mGPS and there were significantdifferences among the groups(P <0.01).Multivariate analysis identified that age(OR,1.319,95% CI1.068,1.629,P <0.01),TNMstage(OR,2.909,95% CI 2.616,3.234,P <0.01)and mGPS(OR,1.845,95% CI 1.184,2.875,P =0.007)were correlated with the postoperative death rate and they wererisk factors of poor postoperative prognosis(P <0.01).Conclusion mGPS can be used as an early,simple and effective prognostic predictor of postoperative survival for patients with gastric cancer.